Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
作者： M Oishi , N Abe , H Yokoyama , N Kuribayashi , O Tomonaga
DOI: 10.1177/147323001204000245
关键词:
摘要: Objective Glycaemic control is critical to prevent diabetic complications and mortality. This 6-month, open-label, observational study assessed the efficacy safety of switching Japanese patients with type 2 diabetes from neutral protamine Hagedorn (NPH) insulin detemir. Methods Patients (n = 126) receiving basal-bolus therapy NPH plus rapid-acting analogues were recruited. was replaced detemir for 6 months. Glycosylated haemoglobin (HbA(1c)), fasting plasma glucose (FPG), daily levels hypoglycaemia monitored. Nocturnal quality life by related at night questionnaire. Results HbA(1c), FPG body weight all significantly reduced after treatment months, without increasing severe hypoglycaemia. Insulin dose increased over same time. There significant improvements in overall nocturnal life, as well well-being. Conclusions Treatment months resulted substantial benefits, including weight,
sagepub.com
paperity.org参考文章(23)
S. Sreenan, A. Virkamäki, K. Zhang, J. B. Hansen, , Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. International Journal of Clinical Practice. ,vol. 62, pp. 1971- 1980 ,(2008) , 10.1111/J.1742-1241.2008.01939.X
J.-P. Le Floch, M. Levy, H. Mosnier-Pudar, F. Nobels, S. Laroche, S. Gonbert, E. Eschwege, P. Fontaine, , Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT) Diabetes Care. ,vol. 32, pp. 32- 37 ,(2009) , 10.2337/DC08-0332
Stephen C. Woods, David A. D'Alessio, Central Control of Body Weight and Appetite The Journal of Clinical Endocrinology and Metabolism. ,vol. 93, ,(2008) , 10.1210/JC.2008-1630
Kjeld Hermansen, Lene S Mortensen, Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus Drug Safety. ,vol. 30, pp. 1127- 1142 ,(2007) , 10.2165/00002018-200730120-00005
Masashi Kobayashi, Katsuya Yamazaki, Koichi Hirao, Mariko Oishi, Azuma Kanatsuka, Mikio Yamauchi, Hirofumi Takagi, Koichi Kawai, The status of diabetes control and antidiabetic drug therapy in Japan—A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1) Diabetes Research and Clinical Practice. ,vol. 73, pp. 198- 204 ,(2006) , 10.1016/J.DIABRES.2006.01.013
P. C. Bartley, M. Bogoev, J. Larsen, A. Philotheou, Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial Diabetic Medicine. ,vol. 25, pp. 442- 449 ,(2008) , 10.1111/J.1464-5491.2007.02407.X
A. E. Pontiroli, L. Miele, A. Morabito, Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes, Obesity and Metabolism. ,vol. 13, pp. 1008- 1019 ,(2011) , 10.1111/J.1463-1326.2011.01433.X
Pierre Fontaine, Henri Gin, Michel Pinget, Charles Thivolet, Hélène Hanaire, Jean-Jacques Robert, Michel Marre, Srishyla Venkatanarasimhachar, Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Advances in Therapy. ,vol. 26, pp. 535- 551 ,(2009) , 10.1007/S12325-009-0033-6
I. W. Campbell, Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? International Journal of Clinical Practice. ,vol. 64, pp. 791- 801 ,(2010) , 10.1111/J.1742-1241.2009.02292.X
Francesca Porcellati, Geremia B. Bolli, Carmine G. Fanelli, Pharmacokinetics and Pharmacodynamics of Basal Insulins Diabetes Technology & Therapeutics. ,vol. 13, ,(2011) , 10.1089/DIA.2011.0038